Shani Waninger

Director, Clinical Development at Advanced Brain Monitoring

Summary
Ph.D. Biochemistry, Johns Hopkins University and over 14 years postdoctoral
experience; in depth knowledge of virology drug discovery and development
6 years Project Leader of infectious disease drug discovery and development
program
Extensive experience in medical and scientific writing including IND filings, SBIR
NIH grants, peer reviewed manuscripts, patent applications, research posters,
marketing materials, press releases and research program summaries
Exemplary managerial, problem solving and communication skills coupled with
demonstrated multitasking abilities
Proven ability to both lead and contribute to crossfunctional teams and deliver on
project goals with aggressive timelines
Established track record for building collaborative relationships with academic
investigators, clinicians and key opinion leaders
Experience :
Advanced Brain Monitoring (July 2014 - Present)
Director, Clinical Development
Cosmo Bio USA (December 2010 - December 2012)
Scientific Communication Specialist
Scientific and technical writing for press release, product descriptions, web site
content and advertisements
Advertisement design for print and banner ads for scientific journals using Adobe
CS5
Cosmo Bio USA company website design and maintenance
HTML email campaign design and distribution
Representation of the company at scientific conferences
Proficiency in Photoshop, Flash, Dreamweaver, Microsoft Office
Adventrx Pharmaceuticals (April 2004 - October 2009)
Associate Director, Research and Development

 Project Team Leader and management of broad spectrum antiviral drug discovery
and development programs
Lead author on SBIR NIH grants, peer reviewed manuscripts, pharm/tox, clinical
and CMC section of IND filings, patent applications, research posters, marketing
materials and press releases
Designed and presented infectious disease and oncology research program
summaries to pharmaceutical and biotech companies for new business partnerships
and licensing opportunities
Represented the company at national and international infectious disease
conferences and presented antiviral research programs
Established and maintained collaborative relationships with national and
international infectious disease KOLs and potential business partners
Expanded the companys Intellectual Property portfolio in HIV and human and
avian influenza with application to therapeutic treatment of infected patients
Lead author on press release, IND filings, SBIR NIH grants, peer reviewed
manuscripts, patent applications and research program summaries
Designed, supervised and interpreted screening, efficacy and mechanistic antiviral
studies for therapeutics to HIV, human and avian influenza, HCV, WNV and
rhinovirus
Design and monitoring of outsourced pharmacology and toxicology for antiviral
and oncology drug candidates
Design, supervision, execution and interpretation of screening, efficacy and
mechanistic antiviral studies on small molecule therapeutics for HIV, human and
avian influenza, west nile virus and herpes simplex virus
Developed assays for higher throughput screening and efficacy studies of antiviral
drug candidates
Implemented and supervised BSL-2 and BSL-3 and trained all personnel
Immusol (April 2000 - April 2004)
Senior Scientist
Developed and established combinatorial ribozyme libraries and identified novel
therapeutic drug targets for HIV, HCV and rhinovirus
Validated drug targets and identified diverse affected steps in the viral replication
cycle using siRNA technology

 Developed and implemented assays for screening and validation of novel

therapeutic drug targets
Characterized the mechanism of identified and validated gene targets through
cellular and enzymatic virology methodology
Led a research group of scientist in discovery of infectious disease drug targets
Maintained and supervised BSL-3 and trained all BSL-3 scientists
University of California (1997 2000)
Postdoctoral Fellow
Isolated HIV Pre-integration Complexes and developed model to study mechanism
of nuclear import and integration
Characterized mechanism of specific steps of HIV integration using radiolabeled
DNA fragment substrates corresponding to integration intermediates and purified
virally encoded proteins
Developed a purification method for HIV integrase and integrase fragments
Created HIV integrase variant virus through site directed mutagenesis,
transfection and amplification of virus
Supervised and trained graduate and undergraduate students in BSL-2 and BSL-3
cell culture and molecular biology studies
Johns Hopkins University (1991 to 1997)
Doctoral Student
Advisor: Dr. John J. Scocca
Thesis Topic: Intasome Assembly during Site Specific Recombination of HP1
Identified and characterized key mechanistic steps in the integration of a HP1
including protein:protein and protein:DNA interactions through biochemical and
molecular biology methods
Established a collaboration with leading structural scientists at the National
Institutes of Health to solve the structure of HP1 integrase through x-ray
crystallography
Undergraduate Research (1990 to 1991)
Advisor
Dr. Alan C. Leonard
Research Topic: DNA Replication of Escherichia coli: Binding of DnaA to OriC DNA

Skills & Expertise:

Drug Discovery, Molecular Biology, Cell Culture, Biochemistry, Infectious Diseases,
Assay Development, Virology, DNA, Clinical Research, Transfection, ELISA, Cell,
Validation
Education :
The Johns Hopkins University (1991 1997)
Ph.D., Biochemistry
Florida Institute of Technology (1988 1991)
Bachelor of Science (BS), Molecular Biology